ClinicalTrials.gg
RecruitingNCT06680583SIUpdated Mar 17, 2026

Utilizing of Physiological Parameters Predict the Prognosis of Cirrhotic Patients With Gastrointestinal Bleeding

An observational study in Liver Cirrhosis and Gastrointestinal Bleeding, sponsored by St. Martin De Porress Hospital. Recruiting at 1 site in Taiwan. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by St. Martin De Porress Hospital · Observational

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
150
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 35 studies in Liver Cirrhosis with a site in Taiwan — 6 open to participants now, 7 under way, 1 of them phase 3. Liver Cirrhosis · Taiwan.

Planned enrollment
11th of 14
150 · median 200
Started
2024
with 2 others
Observational
14 of 35
2 open now
Registered
32nd of 35
by date

Among the 35 studies in Liver Cirrhosis with a site in Taiwan, this one is the 11th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2024, is one of 14 observational ones, and was the 32nd registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

6 of the 35 studies in Liver Cirrhosis with a site in Taiwan are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Liver Cirrhosis with a site in Taiwan, or all of them as a file.
02

Study summary

Can physiological indicators such as quick Sequential Organ Failure Assessment , Shock Index, and its derived indicators such as Modified Shock Index , Age Shock Index and Respiratory Adjusted Shock Index accurately predict the prognosis of cirrhosis patients with gastrointestinal bleeding? To explore the improvement of emergency and critical care patient management.

Read the detailed description

Cirrhosis is a common chronic liver disease with gastrointestinal bleeding being one of its complications. Gastrointestinal bleeding is quite common in patients with cirrhosis, but its prognosis is difficult to accurately predict. In current clinical practice, critical care physicians often use physiological indicators to assess the risk level of patients. Among them, the Shock Index and its derived indicators such as the Modified Shock Index, Age Shock Index, and Respiratory Adjusted Shock Index have been widely used in other fields, but their actual value in patients with cirrhosis complicated by gastrointestinal bleeding is not yet clear.

The prognosis of cirrhosis patients with gastrointestinal bleeding affects the quality of life and survival of the patients, thus necessitating the establishment of a reliable prognostic assessment tool to assist critical care physicians in making rapid treatment decisions. The motivation of this study is to explore the application value of Shock Index-related indicators in predicting the prognosis of cirrhosis patients with gastrointestinal bleeding, in order to improve the medical efficiency for this specific group of critically ill patients.

03

Conditions studied

  • Liver Cirrhosis
  • Gastrointestinal Bleeding

Keywords

  • cirrhosis
  • gastrointestinal bleeding
  • physical indicator
  • shock index
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

cirrhosis with gastrointestinal bleeding

Eligibility criteria

Inclusion Criteria: cirrhosis with gastrointestinal bleeding -

Exclusion Criteria: no complete medical record and trauma patient

-

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • cirrhosis

    cirrhosis with gastrointestinal bleeding

    Other: physical indicators such as shock index relatives

Interventions

  • Otherphysical indicators such as shock index relatives

    shock index relatives indicators used in the prediction of cirrhosis with gastrointestinal bleeding

    Also known as: MSI, Age SI, RASI

06

What researchers measure

Primary outcomes

  1. shock index= heart rate / systolic blood pressure normal range:0.5-0.7 Modified shock index = heart rate/mean arterial pressure(MAP) age shock index = SI x age number respiratory adjusted shock index(RASI) = HR/SBP × RR/10. MAP = DP + 1/3(SP - DP)

    find the shock index relatives indicators in the prognosis prediction of cirrhosis with gastrointestinal bleeding

    Time frame: through study completion, an average of 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — This study include the medical privacy of cirrhosis.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Mar 2027, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Nov 8, 2024
StartActual
Nov 1, 2024
Primary completionEst.
Mar 11, 2027
CompletionEst.
Mar 11, 2027
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06680583
Lead sponsor
St. Martin De Porress Hospital
Responsible party
Chia-hsi Chen (Emergency and Critical Care Physician, St. Martin De Porress Hospital) — Principal investigator
First posted
Nov 8, 2024
Start date
Nov 1, 2024
Primary completion
Mar 11, 2027 (estimated)
Completion
Mar 11, 2027 (estimated)
Last update
Mar 17, 2026

Study contacts

Chia-Hsi Chen, Physician
Contact
urologist3509@gmail.com
886-5-2756000 ext. 3708
Chung-Jing Wang, professor
Contact
medicine@stm.org.tw
886-5-2756000 ext. 3708
Yeong-Chin Jou Jou, professor
study director · St. Martin De Porres Hospital Education and Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion